FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:731-739 February 16, 2006 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In this review, we define hepatotoxicity as injury to the liver that is associated with impaired liver function caused by exposure to a drug or another noninfectious agent. The distinction between injury and function is important, because it is mainly when function is impaired that symptoms and clinically significant disease follow. We are especially concerned with serious drug-related hepatotoxicity that is disabling or life-threatening or that requires hospitalization. Although drug-related hepatotoxicity is uncommon — for many drugs, the reported incidence is between 1 in 10,000 and 1 in 100,000 patients¹ — its true incidence is difficult to determine. The numbers . . . [Full Text of this Article]

Liver Injury and Its Patterns

Injury vs. Function

Clinical Patterns of Hepatotoxicity

Mechanisms of Hepatotoxicity and Susceptibility Factors

Diagnosis

Management

Prevention

The Drug-Development Process

Post-Marketing Surveillance

Monitoring of Liver Tests in Clinical Practice

Pharmacogenomics

Clinical Research

Source Information

From the Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Medical College, Philadelphia (V.J.N.); and the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md. (J.R.S.).

Address reprint requests to Dr. Navarro at 132 South 10th St., Suite 480 Main, Philadelphia, PA 19107, or at victor.navarro@jefferson.edu.

Related Letters:

Drug-Related Hepatotoxicity
McDonnell M. E., Braverman L. E., Patel K. P., McIntyre K., Madariaga M. G., Mumoli N., Cei M., Cosimi A., Navarro V. J., Senior J. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2191-2193, May 18, 2006. Correspondence

This article has been cited by other articles:

• McGoon, M. D., Frost, A. E., Oudiz, R. J., Badesch, D. B., Galie, N., Olschewski, H., McLaughlin, V. V., Gerber, M. J., Dufton, C., Despain, D. J., Rubin, L. J. (2009). Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. Chest 135: 122-129 [Abstract] [Full Text]  
• Lee, S.-T., Wu, T.-T., Yu, P.-Y., Chen, R.-M. (2009). Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J Anaesth 102: 80-89 [Abstract] [Full Text]  
• Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., de Graaf, D. (2008). Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury. Toxicol Sci 105: 97-105 [Abstract] [Full Text]  
• El-Naggar, M. H., Helmy, A., Moawad, M., Al-Omary, M., Al-Kadhi, Y., Habib, B. (2008). Late-Onset Rosiglitazone-Associated Acute Liver Failure in a Patient with Hodgkin's Lymphoma. The Annals of Pharmacotherapy 42: 713-718 [Abstract] [Full Text]  
• Nichols, W. G., Steel, H. M., Bonny, T., Adkison, K., Curtis, L., Millard, J., Kabeya, K., Clumeck, N. (2008). Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140). Antimicrob. Agents Chemother. 52: 858-865 [Abstract] [Full Text]  
• Firenzuoli, F., Gori, L., di Sarsina, P. R. (2008). Black Cohosh Hepatic Safety: Follow-up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature. Evid Based Complement Alternat Med 0: nen009v1-nen009 [Abstract] [Full Text]  
• Nisly, S. A, Ray, S. M, Moye, R. A (2007). Tobramycin-Induced Hepatotoxicity. The Annals of Pharmacotherapy 41: 2061-2065 [Abstract] [Full Text]  
• Bottenberg, M. M, Wall, G. C, Harvey, R. L, Habib, S. (2007). Oral Aloe Vera-Induced Hepatitis. The Annals of Pharmacotherapy 41: 1740-1743 [Abstract] [Full Text]  
• DeSanty, K. P, Amabile, C. M (2007). Antidepressant-Induced Liver Injury. The Annals of Pharmacotherapy 41: 1201-1211 [Abstract] [Full Text]  
• Comelli, M. C., Mengs, U., Schneider, C., Prosdocimi, M. (2007). Toward the Definition of the Mechanism of Action of Silymarin: Activities Related to Cellular Protection From Toxic Damage Induced by Chemotherapy. Integr Cancer Ther 6: 120-129 [Abstract]  
• Hirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., Hwang, S., Leonard, E. M., Almstead, N. G., Ju, W., Peltz, S. W., Miller, L. L. (2007). Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers. J Clin Pharmacol 47: 430-444 [Abstract] [Full Text]  
• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Bies, R. R. (2006). Highlights and Book Reviews. J Clin Pharmacol 46: 1052-1056 [Full Text]  
• McDonnell, M. E., Braverman, L. E., Patel, K. P., McIntyre, K., Madariaga, M. G., Mumoli, N., Cei, M., Cosimi, A., Navarro, V. J., Senior, J. R. (2006). Drug-related hepatotoxicity.. NEJM 354: 2191-2193 [Full Text]